Table of Content

Chapter 1 Foreword
Research Review Scope

Chapter 2 Global Market for Anti-obesity Drugs (PHM281A)
Anti-obesity Drugs
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Market Outlook
Market Summary
Market Overview of Anti-obesity Drugs
Definitions of Adult Obesity and Overweight
Rising Prevalence of Obesity
Impact of Obesity on Global Economy
Increasing Awareness Regarding Obesity
Global Market for Anti-obesity Drugs, by Type
Prescription Drugs
Over-the-Counter Anti-obesity Drugs
Global Market for Anti-obesity Drugs, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Market for Anti-obesity Drugs, by Region
North America
Europe
Asia-Pacific
Rest of the World
ESG Developments of Anti-obesity Drugs
Importance of ESG in Anti-obesity Drugs Industry
ESG Pillars in the Anti-obesity Drug Industry
ESG Ratings and Metrics: Understanding the Data
ESG Practices in the Anti-obesity Drug Industry

Chapter 3 Drugs of Abuse Testing: Technologies and Global Markets (PHM013J)
Drugs of Abuse Testing
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Summary and Highlights
Market and Technology Background of Drugs of Abuse Testing
Overview
Testing Technologies
Single Tests vs. Multiparameter Tests
DOA Screening
Porter’s Five Forces Analysis of Drugs of Abuse Testing
Market Dynamics of Drugs of Abuse Testing
Market Drivers
Market Restraints
Market Opportunities
Regulatory Scenario of Drugs of Abuse Testing
North America
South America
Central America and the Caribbean
Europe
Asia-Pacific
Global Drugs of Abuse Testing Market, by Drug Type
Alcohol
Amphetamine and Methamphetamine
Cannabis/Marijuana
Cocaine
Opioids
Others
Global Drugs of Abuse Testing Market, by End User
Drug Testing Laboratories
Hospitals
Workplaces
Others
Market Breakdown of Drugs of Abuse Testing, by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Chapter 4 Global Markets for Bioengineered Protein Drugs (BIO009H)
Bioengineered Protein Drugs
Study Goals and Objectives
Scope of This Report
Market Summary
Market and Technology Background of Bioengineered Protein Drugs
Protein Drugs Overview
Bioengineered Protein Drugs
Manufacturing Technologies of Bioengineered Protein Drugs
Fractionation/Extraction from Natural Sources (Human/Animal)
Microbial Fermentation and Bioreactors
Transgenics
Mammalian Cell Culture
Market Dynamics of Bioengineered Protein Drugs
Market Driver
Market Challenges
Market Breakdown of Bioengineered Protein Drugs by Drug Type
Overview
Monoclonal Antibodies (mAbs)
Peptide Hormones
Vaccines
Fusion Proteins
Blood Factors
Peptide Antibiotics
Cytokines
Therapeutic Enzymes
Market Breakdown of Bioengineered Protein Drugs, by Disease
Overview
Market Breakdown of Bioengineered Protein Drugs, by Region
North America Market Revenue, by Drug Type
Europe Market Revenue, by Drug Type
Emerging Markets Revenue, by Drug Type
Regulatory Aspects and New Approvals of Bioengineered Protein Drugs Market
New Approvals
Emerging Trends/Upcoming Technologies in the Market
Bi- and Multi-Specific Antibodies
Key Trends in Biopharmaceutical Industry

Chapter 5 Global Market for Pain Management Drugs and Devices (HLC026G)
Pain Management Drugs and Device
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Market Outlook
Market Summary
Highlights of the Market for Pain Management Drugs and Devices
Market Overview of Pain Management Drugs and Device
History of Pain and Pain Treatment
The Perception of Pain
Types of Pain
Assessment of Pain
How Pain is Diagnosed
How Pain is Treated
Market Dynamics of Pain Management Drugs and Device
Market Drivers
Market Restraints
Market Challenges
Market Breakdown of Pain Management Drugs and Device, by Product
Pharmaceuticals
Pain Management Devices
Market Breakdown of Pain Management Drugs and Device, by Application
Musculoskeletal Pain
Post-operative Pain
Neuropathic Pain
Cancer Pain
Migraine/Headache
Other Applications
Market Breakdown of Pain Management Drugs and Device, by Region
North America
Europe
Asia-Pacific
Rest of the World
ESG Development of Pain Management Drugs and Device
Introduction to ESG
Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
Case Study

Emerging Technologies of Pain Management Drugs and Device
Overview
Technology Advancements in Opioid Drugs
Technology Advancements in Non-narcotic Drugs
Technology Advancements in Neuromodulation Devices
Technology Advancements in Infusion Pumps
Trends in Pain Management

Chapter 6 Appendix
Methodology
Analyst’s Credentials



List of Figures

List of Figures
Figure 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
Figure 2 : Global Market for Anti-obesity Drugs, by Drug Type, 2021-2028
Figure 3 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
Figure 4 : Global Market Shares of Anti-obesity Drugs, by Region, 2021-2028
Figure 5 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
Figure 6 : Annual Self-reported Alcohol-impaired Driving Episodes Among U.S. Adults, 2010-2020
Figure 7 : Legal Adult-Use Cannabis Sales Worldwide, 2020-2025*
Figure 8 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
Figure 9 : Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
Figure 10 : Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
Figure 11 : Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021
Figure 12 : Snapshot of Global Market for Bioengineered Protein Drugs, by Region
Figure 13 : Global Market Shares of Bioengineered Protein Drugs, by Region, 2021
Figure 14 : NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
Figure 15 : Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
Figure 16 : Global Market for Pain Management Drugs and Devices, by Product, 2020-2028
Figure 17 : Global Market for Pain Management Drugs and Devices, by Region, 2020-2028
Figure 18 : Pain Management Techniques
Figure 19 : Pain Management Drugs and Devices: Market Dynamics
Figure 20 : Common Chronic Pain: Reasons
Figure 21 : Cancer Incidence, by Region, 2020 vs. 2040
Figure 22 : Percentage of Global Population Above 65 Years, 2018-2022
Figure 23 : Global Market Shares of Pain Management Drugs and Devices , by Product, 2022
Figure 24 : Global Market Shares of Pain Management Pharmaceuticals, by Product, 2022
Figure 25 : Global Market Shares of Pain Management Devices, by Type, 2022
Figure 26 : Global Market Shares of Pain Management Drugs and Devices, by Application, 2022
Figure 27 : Classification of Neuropathic Pain
Figure 28 : Causes of Cancer Pain
Figure 29 : Burn Pain Management Approach
Figure 30 : Global Market Shares of Pain Management Drugs and Devices, by Region, 2022
Figure 31 : ESG Pillars
Figure 32 : Advantages of ESG for Companies
Figure 33 : ESG-Adoption Level across Industries
Figure 34 : Hospitals: Sustainability Priorities
Figure 35 : Novartis: ESG Rating
Figure 36 : Novartis: Major ESG Activities, 2022

List of Tables

List of Tables
Table 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
Table 2 : Definitions of Adult Obesity and Overweight
Table 3 : Number of People, Aged Over 5 Years, and Percentage of the Population With Overweight or Obesity, 2020–2035
Table 4 : Global Obesity Trends for Children and Adolescents, Aged 5 to 19 Years, by Gender, 2020–2035
Table 5 : Global Obesity Trends for Adults, Aged 20 Years and Above, by Gender, 2020-2035
Table 6 : Global Economic Impact of High BMI (BMI ?25kg/m?), 2020–2035
Table 7 : Global Market for Anti-obesity Drugs, by Drug Type, Through 2028
Table 8 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
Table 9 : Global Market for Anti-obesity Drugs, by Region, Through 2028
Table 10 : ESG Ratings and Metrics of Anti-obesity Drugs
Table 11 : Environmental Performance of Anti-obesity Drugs
Table 12 : Social Performance of Anti-obesity Drugs
Table 13 : Governance Performance of Anti-obesity Drugs
Table 14 : ESG Rankings for Major Anti-obesity Drug Companies, 2023*
Table 15 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
Table 16 : Cutoff Concentrations for Initial and Confirmatory Drug Tests in Urine
Table 17 : Deaths from Tobacco, Alcohol and Drugs, Across Countries, 2019
Table 18 : Commonly Abused Drugs
Table 19 : Prevalence of Drug Use in General, Population Across Region, 2020
Table 20 : Global Drug Seizure, by Drug Type, 2020
Table 21 : U.S. Drug Testing Legislation, by State, 2017
Table 22 : European Drug Testing Legislation, by Country
Table 23 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
Table 24 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
Table 25 : Characteristics of Large Molecule/Protein Drugs
Table 26 : Bioengineered Protein Drugs vs. Chemically Synthesized Drugs
Table 27 : Selected Protein Drugs Made, by Fractionation
Table 28 : Selected Therapeutic Drugs Produced, by Microbial Fermentation
Table 29 : Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms
Table 30 : Selected Protein Drugs Made, by Cell Culture
Table 31 : Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050
Table 32 : Global Pipeline Molecules, by Type, Through 2021
Table 33 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
Table 34 : Percentage of Major Proteins Present in Different Fractions After Cohn’s Fractionation Method
Table 35 : Global Market for Bioengineered Protein Drugs, by Disease, Through 2027
Table 36 : Global Market for Bioengineered Protein Drugs, by Region, Through 2027
Table 37 : Newly Approved Monoclonal Antibodies (mAbs), January 2021–December 2022
Table 38 : Newly Approved Peptide Hormones and Drugs, January 2021-December 2022
Table 39 : Newly Approved Vaccines, January 2021–December 2022
Table 40 : Vaccine Candidates in Clinical Phase, January 2021–December 2022
Table 41 : Newly Approved Blood Factors, January 2021-December 2022
Table 42 : Newly Approved Peptide Antibiotics, January 2021-December 2022
Table 43 : Newly Approved Therapeutic Enzymes, January 2021-December 2022
Table 44 : Newly Approved Cytokines, January 2021-December 2022
Table 45 : Newly Approved Fusion Protein, January 2021-December 2022
Table 46 : Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023
Table 47 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
Table 48 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
Table 49 : Objective Signs of Pain
Table 50 : Prevalence of Chronic Pain in Older Adults, by Site
Table 51 : Opioid Lawsuit Settlements
Table 52 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
Table 53 : FDA Pain Management Drug Approvals, 2020-2023
Table 54 : Pain Management Major Drugs, by Company
Table 55 : Emerging Pain Therapeutics
Table 56 : Global Market for Pain Management Pharmaceuticals, by Product, Through 2028
Table 57 : Global Market for Pain Management Devices, by Type, Through 2028
Table 58 : Global Market for Pain Management Drugs and Devices, by Application, Through 2028
Table 59 : Cumulative Volumes of Hip and Knee Procedures, 2012-2021
Table 60 : Neuropathic Pain Medication
Table 61 : Cancer Pain Medication
Table 62 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
Table 63 : ESG Ranking of Major Pharma Players for Pain Therapeutics, 2022
Table 64 : ESG Rankings for Major Pain Management Drug and Device Companies, 2023*
Table 65 : ESG: Environmental Overview
Table 66 : ESG: Social Overview
Table 67 : ESG: Governance Overview